BioSpace News Archive

QYNAPSE, a medical technology company, announced that it received U.S. Food and Drug Administration (FDA) 510(k) clearance for its QyScore® software.

Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action filed on behalf of investors that purchased or acquired the securities of Adamas Pharmaceuticals, Inc. (“Adamas” or the “Company”) (NASDAQ: ADMS) between August 8, 2017, and September 30, 2019, inclusive (the “Class Period”)

This new study by The Beljanski Foundation on reducing BPH with the Pao pereira extract is published in the high-profile journal Scientific Reports on Nature.com

New portfolio of polycarbonate resins highly suited to drug delivery applications

Lakes Dermatology is the only clinic in Nevada with this innovative treatment technology

The number of confirmed cases of coronavirus (2019-nCoV) has reached 17,489, with 362 deaths, as of the morning of Feb 3, according to the interactive map provided by Johns Hopkins CSSE (Center for Systems Science and Engineering)

Angelini Pharma Inc. U.S., an international healthcare company headquartered in Maryland, is tackling the epidemic of healthcare-acquired infections (HAIs) with their new line of infection prevention products

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review a supplemental New Drug Application (sNDA) for RECARBRIO™ (imipenem, cilastatin, and relebactam) to treat adult patients with hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP) caused by certain susceptible Gram-negative microorganisms.

Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) disorders, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for ANAVEX®2-73

Pluristem Therapeutics Inc., a leading regenerative medicine company developing a platform of novel biological products, announced results from a market access comprehensive research study conducted by Marwood Group, a healthcare advisory firm, for the critical limb ischemia market in the U.S.